New antibiotics authorized by referral agencies. Brief communication
Resumen
N/A
Referencias
1. European Medicines Agency. (22 de marzo de 2024). Emblaveo. https://www.ema.europa.eu/en/medicines/human/EPAR/emblaveo
2. Pfizer Inc. (1 de Junio de 2023). Phase 3 studies of pfizer’s novel antibiotic combination offer new treatment hope for patients with multidrug-resistant infections and limited treatment options | pfizer. https://www.pfizer.com/news/press-release/pressrelease-detail/phase-3-studies-pfizersnovel-antibiotic-combination-offer
3. Sader, H. S., Carvalhaes, C. G., Arends, S. J. R., Castanheira, M., & Mendes, R. E. (2020). Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. Journal of Antimicrobial Chemotherapy, 76(3), 659-666. https://doi.org/10.1093/jac/dkaa504
4. Food & Drug Administration. (3 deCommissioner, O. of the. (3 de abril de 2024). Fda approves new antibiotic for three different uses. FDA. https://www.fda.gov/news-events/press-announcements/fdaapproves-new-antibiotic-three-differentuseshttps://www.fda.gov/news-events/press-announcements/fda-approves-newantibiotic-three-different-uses
5. Organización Mundial de la Salud. (17 de noviembre de 2021). Global antimicrobial resistance and use surveillance system (glass) report: 2022. https://www.who.int/publications-detailredirect/9789240062702/
6. Organización Mundial de la Salud (17 de noviembre de 2021). Resistencia a los antimicrobianos. https://www.who.int/es/news-room/fact-sheets/detail/antimicrobialresistance
7. Organización Mundial de la Salud (2022). La resistencia a los antimicrobianos y el Marco de Cooperación de las Naciones Unidas para el Desarrollo Sostenible: orientaciones para los equipos de las Naciones Unidas en los países [Antimicrobial resistance and the United Nations Sustainable Development Cooperation Framework: guidance for United Nations country teams]. https://www.fao.org/3/cb6755es/cb6755es.pdf
